Tag:
Crucell
Latest Headlines
Latest Headlines
UPDATED: Crucell and Royal DSM pull the plug on biosimilar JV
A joint venture marrying the protein and antibody development technology of Crucell with the manufacturing knowhow of Royal DSM has collapsed.
Breakthrough trial protects monkeys from HIV-like virus
Scientists for the first time have successfully used a vaccine to protect monkeys from contracting their version of the AIDS virus. Johnson & Johnson ( $J&J ) subsidiary Crucell NV of the
Vaccine combo shows early promise against AIDS
A new AIDS vaccine that combines two experimental therapies has shown promise in monkeys. The animals were given a vaccine developed by Johnson & Johnson ( $JNJ ) subsidiary Crucell combined with a...
Crucell and Scripps find antibody for universal flu vax
Researchers at Crucell and the Scripps Research Institute have discovered a new antibody that could lead to a universal flu vaccine. According to animal test results, the antibody, CR6261,
Unicef price postings aim for lower-cost vaccines
India is the low-cost supplier of vaccines in most Unicef categories, according to supplier pricing data listed by the UN's children's advocate organization for the first time. In one case, nearly a
GAVI board hit with conflict of interest woes
The board of the Global Alliance for Vaccines and Immunizations is preparing for its July shakeup. And as GlaxoSmithKline steps down and vaccine maker Crucell takes its place, some organizations have
Crucell wins back WHO with plant power fixes
One of the dark clouds hanging over Johnson & Johnson is lifting. The World Health Organization has green-lighted Dutch vaccine-maker--and J&J quarry--Crucell to resume supplying the
WHO clears Crucell to put vax back on market
Crucell can exit the penalty box. After a review of manufacturing problems involving its vaccine Quinvaxem, the Dutch company now has the World Health Organization's blessing to resume selling the
J&J/Crucell deal might snag on bid issues
While J&J may consider lowering its bid for Crucell because of manufacturing issues, some Crucell shareholders are determined to hold out for more. Van Herk, the second largest Crucell
J&J offers $2.3B in bid for Crucell shares
Despite a recent snafu in Crucell's manufacturing division, Johnson & Johnson has formally stepped up to the table with an offer to buy out all the shares of the Dutch vaccine company for $2.3
